321 related articles for article (PubMed ID: 25862591)
21. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
Tomblyn MR; Ewell M; Bredeson C; Kahl BS; Goodman SA; Horowitz MM; Vose JM; Negrin RS; Laport GG
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1051-7. PubMed ID: 21073974
[TBL] [Abstract][Full Text] [Related]
22. Assessment of immune reconstitution status in recipients of a successful hematopoietic stem cell transplant from peripheral blood after reduced intensity conditioning.
Jaime-Pérez JC; Villarreal-Villarreal CD; Méndez-Ramírez N; Vázquez-Garza E; Salazar-Riojas R; Gómez-Almaguer D
Blood Cells Mol Dis; 2016 May; 58():52-6. PubMed ID: 27067489
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenström Macroglobulinemia: A Systematic Review and Meta-analysis.
Parrondo RD; Reljic T; Iqbal M; Ayala E; Tun HW; Kharfan-Dabaja MA; Kumar A; Murthy HS
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e694-e711. PubMed ID: 32616401
[TBL] [Abstract][Full Text] [Related]
24. Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation.
Pollack SM; Steinberg SM; Odom J; Dean RM; Fowler DH; Bishop MR
Biol Blood Marrow Transplant; 2009 Feb; 15(2):223-30. PubMed ID: 19167682
[TBL] [Abstract][Full Text] [Related]
25. The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
Solh MM; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A
Biol Blood Marrow Transplant; 2019 Mar; 25(3):606-612. PubMed ID: 30244109
[TBL] [Abstract][Full Text] [Related]
26. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.
Baron F; Storb R; Storer BE; Maris MB; Niederwieser D; Shizuru JA; Chauncey TR; Bruno B; Forman SJ; McSweeney PA; Maziarz RT; Pulsipher MA; Agura ED; Wade J; Sorror M; Maloney DG; Sandmaier BM
J Clin Oncol; 2006 Sep; 24(25):4150-7. PubMed ID: 16896000
[TBL] [Abstract][Full Text] [Related]
27. External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation.
Shouval R; Fein JA; Shouval A; Danylesko I; Shem-Tov N; Zlotnik M; Yerushalmi R; Shimoni A; Nagler A
Blood Adv; 2019 Jun; 3(12):1881-1890. PubMed ID: 31221661
[TBL] [Abstract][Full Text] [Related]
28. Pretransplantation Plasma ST2 Level as a Prognostic Biomarker of 1-Year Nonrelapse Mortality in Allogeneic Hematopoietic Cell Transplantation.
Gjærde LK; Ostrowski SR; Schierbeck F; Andersen NS; Friis LS; Kornblit B; Petersen SL; Schjødt I; Sengeløv H
Transplant Cell Ther; 2023 Feb; 29(2):97.e1-97.e6. PubMed ID: 36375798
[TBL] [Abstract][Full Text] [Related]
29. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.
Keller JW; Andreadis C; Damon LE; Kaplan LD; Martin TG; Wolf JL; Ai WZ; Venstrom JM; Smith CC; Gaensler KM; Hwang J; Olin RL
J Geriatr Oncol; 2014 Jul; 5(3):238-44. PubMed ID: 24894413
[TBL] [Abstract][Full Text] [Related]
30. CD34
Barba P; Martino R; Zhou Q; Cho C; Castro-Malaspina H; Devlin S; Esquirol A; Giralt S; Jakubowski AA; Caballero D; Maloy M; Papadopoulos EB; Piñana JL; Fox ML; Márquez-Malaver FJ; Valcárcel D; Solano C; López-Corral L; Sierra J; Perales MA
Biol Blood Marrow Transplant; 2018 May; 24(5):964-972. PubMed ID: 29305194
[TBL] [Abstract][Full Text] [Related]
31. Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia.
Khalil MMI; Lipton JH; Atenafu EG; Gupta V; Kim DD; Kuruvilla J; Viswabandya A; Messner HA; Michelis FV
Eur J Haematol; 2018 Feb; 100(2):198-205. PubMed ID: 29168234
[TBL] [Abstract][Full Text] [Related]
32. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.
Sorror ML; Storb RF; Sandmaier BM; Maziarz RT; Pulsipher MA; Maris MB; Bhatia S; Ostronoff F; Deeg HJ; Syrjala KL; Estey E; Maloney DG; Appelbaum FR; Martin PJ; Storer BE
J Clin Oncol; 2014 Oct; 32(29):3249-56. PubMed ID: 25154831
[TBL] [Abstract][Full Text] [Related]
33. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
[TBL] [Abstract][Full Text] [Related]
34. Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myelogenous leukemia: a study from the center for international blood and marrow transplantation research.
Foran JM; Pavletic SZ; Logan BR; Agovi-Johnson MA; Pérez WS; Bolwell BJ; Bornhäuser M; Bredeson CN; Cairo MS; Camitta BM; Copelan EA; Dehn J; Gale RP; George B; Gupta V; Hale GA; Lazarus HM; Litzow MR; Maharaj D; Marks DI; Martino R; Maziarz RT; Rowe JM; Rowlings PA; Savani BN; Savoie ML; Szer J; Waller EK; Wiernik PH; Weisdorf DJ
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1102-8. PubMed ID: 23632091
[TBL] [Abstract][Full Text] [Related]
35. Hematopoietic Stem Cell Transplant Recipients Surviving at Least 2 Years from Transplant Have Survival Rates Approaching Population Levels in the Modern Era of Transplantation.
Kliman D; Nivison-Smith I; Gottlieb D; Hamad N; Kerridge I; Purtill D; Szer J; Ma D
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1711-1718. PubMed ID: 32194285
[TBL] [Abstract][Full Text] [Related]
36. Diffuse alveolar hemorrhage is most often fatal and is affected by graft source, conditioning regimen toxicity, and engraftment kinetics.
Keklik F; Alrawi EB; Cao Q; Bejanyan N; Rashidi A; Lazaryan A; Arndt P; Dincer EH; Bachanova V; Warlick ED; MacMillan ML; Arora M; Miller J; Brunstein CG; Weisdorf DJ; Ustun C
Haematologica; 2018 Dec; 103(12):2109-2115. PubMed ID: 30076172
[TBL] [Abstract][Full Text] [Related]
37. Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation.
ElSawy M; Storer BE; Pulsipher MA; Maziarz RT; Bhatia S; Maris MB; Syrjala KL; Martin PJ; Maloney DG; Sandmaier BM; Storb R; Sorror ML
Br J Haematol; 2015 Aug; 170(4):574-83. PubMed ID: 25945807
[TBL] [Abstract][Full Text] [Related]
38. Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant center.
Guilfoyle R; Demers A; Bredeson C; Richardson E; Rubinger M; Szwajcer D; Seftel MD
Bone Marrow Transplant; 2009 Jan; 43(2):133-9. PubMed ID: 18762762
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma.
Wirk B; Fenske TS; Hamadani M; Zhang MJ; Hu ZH; Akpek G; Aljurf MD; Armand P; Ayala E; Bachanova V; Bolwell B; Cairo MS; Cashen A; Chen YB; Costa LJ; Farhan S; Freytes CO; Gajewski JL; Gibson J; Hale GA; Holmberg LA; Hsu JW; Inwards DJ; Kamble RT; Maharaj D; Maziarz RT; Munker R; Nath R; Reddy NM; Reeder CB; Rizzieri DA; Sauter CS; Savani BN; Schouten HC; Sureda A; Vose JM; Waller EK; Wiernik PH; Gale RP; Burns LJ; Saber W
Biol Blood Marrow Transplant; 2014 Jul; 20(7):951-9. PubMed ID: 24641828
[TBL] [Abstract][Full Text] [Related]
40. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
